Regulatory Mechanism of Orphanin FQ in Patients With Chronic Ischemic Heart Failure
Correlation Between Serum Orphanin FQ and β1-AR Autoantibodies in Patients With Chronic Ischemic Heart Failure and Its Regulatory Mechanism
1 other identifier
observational
180
0 countries
N/A
Brief Summary
β 1 adrenergic autoantibody on cardiomyocytes β 1 adrenergic receptor increased the occurrence of malignant arrhythmia in patients with chronic heart failure, accelerated myocardial cell damage, and participated in sudden cardiac death. Our team found for the first time that endogenous orphanin enkephalin promotes arrhythmia after acute myocardial ischemia in rats, and its mechanism includes PKC pathway, regulation of action potential duration and cell membrane surface β 1 adrenoceptor internalization disorder. At the same time, N / OFQ can regulate the level of immune factors, and immune factors participate in the formation of β1-aa. This study will be verified by clinical observation and animal experiments: first, N / OFQ, IL-6 and chronic ischemic heart failure, and β 1-aa; second, relationship between IL-6 gene 572G / C polymorphism and chronic ischemic heart failure correlation of β 1-aa production; last, objective to verify whether N / OFQ is involved in the regulation of IL-6 on chronic ischemic heart failure by knocking out N/ OFQ gene in the animal model of chronic ischemic heart failure. So as to clarify the mechanism of myocardial cell and extracellular injury, and find a new target for the treatment of chronic heart failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 4, 2021
CompletedStudy Start
First participant enrolled
November 1, 2021
CompletedFirst Posted
Study publicly available on registry
November 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 28, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedNovember 3, 2021
October 1, 2021
1.1 years
July 4, 2021
October 25, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Serum orphanin FQ was determined by enzyme linked immunosorbent assay
Serum N/OFQ levels
24 hours
Study Arms (3)
Antibody positive group
Antibody negative group
Health Group
Interventions
Determination of serum β 1-aa content
Eligibility Criteria
During the study period, patients in the Department of Cardiology of the second hospital of Shanxi Medical University were admitted.
You may qualify if:
- Chronic heart failure patients with reduced ejection fraction due to ischemic heart disease.
You may not qualify if:
- Restrictive or hypertrophic cardiomyopathy, hypertensive cardiomyopathy, acute myocarditis, acute coronary syndrome or acute myocardial infarction in the last 2 months, valvular disease (except mitral regurgitation secondary to left ventricular dilation).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
July 4, 2021
First Posted
November 3, 2021
Study Start
November 1, 2021
Primary Completion
November 28, 2022
Study Completion
December 31, 2022
Last Updated
November 3, 2021
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will not share